All Posts

Biochips have emerged as indispensable tools in the healthcare sector, revolutionizing the way diseases are diagnosed, monitored, and treated. These miniature laboratories on a chip offer unparalleled efficiency, sensitivity, and speed in analyzing biological samples, making them invaluable in various medical appli...

Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that in...

ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...

Evenamide (NW-3509)– derived from Newron's ion channel program, tackles schizophrenia with its unique mechanism, balancing glutamate levels and blocking aberrant sodium channel activity to restore neuronal function without compromising normal excitability. Evenamide, based on a new concept in treating inadequat...

Ulotaront (SEP-363856), a novel investigational drug, by Sumitomo Pharma/Otsuka Pharmaceuticals, has shown promise as a potential alternative treatment method for schizophrenia, as it lessens the negative metabolic side effects TAAR1 has emerged as a promising target in the treatment of schizophrenia and other ...

Unlike traditional antipsychotic medications that block dopamine receptors, CVL-231 selectively modulates the M4 receptor in the brain and provides antipsychotic effects without the need for titration. CVL-231, a once-daily medication, with enhanced potential for treatment adherence, seeks to bypass gastrointes...

KarXT, likely to receive the nod from the US FDA by late 2024, will significantly impact the market with the potential to reduce the positive, negative, and cognitive symptoms of schizophrenia. The long-term data is encouraging, signaling that KarXT is not associated with “burdensome side effects” the major imp...

In the landscape of schizophrenia treatment, there are significant gaps that affect patients' lives profoundly. From the foggy terrain of early detection, where symptoms blur the lines between schizophrenia and other mental health conditions, to the daunting landscape of treatment resistance and relapse, where stan...

LYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders compared to traditional daily medications such as Risperdal. A unique capsule design consisting of six polymeric arms connected to a flexible core, encapsulated in a folded star-shaped f...

Despite the urgent need for novel treatments, drug development for cognitive impairment associated with schizophrenia has been challenging, due to limited understanding, high trial failures, and few potential targets in the treatment regime. Iclepertin (BI 425809), an investigational asset, is a GlyT1 inhibitor...